Sponsor & Developer Portfolio

Moderna

Clinical development pipeline, platform architecture, and registered trial tracking for Moderna vaccine candidates.

Candidates

Target Diseases

Linked Studies

Development Phase Distribution

Phase 3 Clinical Trial: 5 Phase 2 Clinical Trial: 5 Approved / Licensed: 4 Regulatory Submission Filed: 2 Discontinued / Inactive: 1 Phase 1 Clinical Trial: 1

Platform Technologies

mRNA: 16 See FDA product page / label: 2

Target Pathogens & Indications

CMV COVID-19 EBV Influenza Lyme disease Melanoma Multiple Sclerosis Norovirus RSV Seasonal influenza Seasonal influenza + COVID-19 (combination) Varicella / Zoster

Vaccine Pipeline Candidates (18)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

View Global Pipeline Matrix →

Approved / Licensed fda-spikevax

SPIKEVAX

Target: COVID-19

Platform: See FDA product page / label

Key Milestone: US-licensed — see product label / ACIP for use; further supplements may expand indication

View Full Clinical Profile → Disease Hub →

Approved / Licensed fda-mresvia

mRESVIA

Target: RSV

Platform: See FDA product page / label

Key Milestone: US-licensed — see product label / ACIP for use; further supplements may expand indication

View Full Clinical Profile → Disease Hub →

Approved / Licensed ctgov-mrna-1345-modernatx-inc

mRESVIA (mRNA-1345 / RSV vaccine)

Target: RSV

Platform: mRNA

Key Milestone: Global commercial distribution; expanded adult age-group trials

View Full Clinical Profile → Disease Hub →

Approved / Licensed mrna-1345-rsv

mRNA-1345 (mRESVIA context / next-gen RSV programs)

Target: RSV

Platform: mRNA

Key Milestone: Label expansions / seasonal updates as disclosed; see licensed RSV page for post-licensure safety

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-mrna-1273-214-modernatx-inc

mRNA-1273.214

Target: COVID-19

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2024-11-15 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 1 Clinical Trial ctgov-mrna-1195-1-modernatx-inc

mRNA-1195.1

Target: EBV

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2026-10-07 (registry estimate)

View Full Clinical Profile →

Phase 2 Clinical Trial ctgov-mrna-1189-modernatx-inc

mRNA-1189

Target: EBV

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2026-10-05 (registry estimate)

View Full Clinical Profile →

Phase 2 Clinical Trial ctgov-mrna-1195-modernatx-inc

mRNA-1195

Target: Multiple Sclerosis

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2029-01-08 (registry estimate)

View Full Clinical Profile →

Phase 2 Clinical Trial ctgov-mrna-1468-modernatx-inc

mRNA-1468

Target: Varicella / Zoster

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2026-06-30 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 2 Clinical Trial ctgov-mrna-1982-modernatx-inc

mRNA-1982

Target: Lyme disease

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2028-11-09 (registry estimate)

View Full Clinical Profile →

Phase 2 Clinical Trial ctgov-mrna-4157-modernatx-inc

mRNA-4157

Target: Melanoma

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2032-11-30 (registry estimate)

View Full Clinical Profile →

Phase 3 Clinical Trial ctgov-mrna-1018-h5-modernatx-inc

mRNA-1018-H5

Target: Influenza

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2027-01-28 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-mrna-1273-modernatx-inc

mRNA-1273

Target: COVID-19

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2027-06-16 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-mrna-1273-variant-containing-formulation-modernatx-inc

mRNA-1273 Variant-containing Formulation

Target: COVID-19

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2026-12-31 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-mrna-1403-modernatx-inc

mRNA-1403

Target: Norovirus

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2027-02-15 (registry estimate)

View Full Clinical Profile →

Phase 3 Clinical Trial ctgov-mrna-1647-modernatx-inc

mRNA-1647

Target: CMV

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2025-11-04 (registry estimate)

View Full Clinical Profile →

Regulatory Submission Filed mrna-1010

mRNA-1010

Target: Seasonal influenza

Platform: mRNA

Key Milestone: Regulatory decision(s) pending across filed jurisdictions (company projection)

View Full Clinical Profile → Disease Hub →

Regulatory Submission Filed mrna-1083

mRNA-1083 (Moderna Combined Influenza + COVID-19 mRNA Vaccine)

Target: Seasonal influenza + COVID-19 (combination)

Platform: mRNA

Key Milestone: FDA target PDUFA action date and ACIP review for 2025-2026 respiratory season

View Full Clinical Profile → Disease Hub →

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →